One Nucleus is delighted to invite you to register for our Life Science Leadership Series: Investment Strategies for Life Sciences, at Chesterford Research Park on 25 September 2013.
There has never been a time when the phrase ‘Cash is King’ has played more heavily on the minds of life science company executives. Out of challenges can emerge innovation and new strategies. However we are seeing:The continuing growth of the corporate venture capital influence alongside more traditional venture capital
- Innovative financing and deal strategies from less traditional sources such as Family Offices
- New initiatives to address the early stage gaps from Government and NGOs, for example the Biomedical Catalyst Fund and the Syncona Fund
- Successful growth of platform companies through revenue-based deals before transitioning to a product discovery and development format
- A focus on accessing the growing overseas collaborative, financial and healthcare markets in the BRIC territories
- Growing interest from institutional and private investors on the public markets, for instance AIM
Presenters and panellists at this event will share their practical experiences in the above areas and debate what is working, what is not working and what companies and investors can do to enhance their chances of success in the current life science landscape.
The event starts with a networking lunch at 13.00, sponsored by Stevenage Bioscience Catalyst, followed by panel discussions all afternoon and a drinks reception finishing at 18.30.
Registering for the Leadership Series entitles delegates to attend a morning session focusing on business opportunities in India starting at 11.15.
For more information on the Life Science Leadership Series: Investment Strategies for Life Sciences, please click here.
Prices:
One Nucleus Gold Members £75 + VAT
One Nucleus Silver Members £175 + VAT
Non Members £275 + VAT
Academics £75 + VAT
(Please contact aline@onenucleus.com for your discount code)
Biotechnology Investment Forum (BIF) 2013
One Nucleus will also be supporting the Babraham Bioscience Technologies' (BBT) Biotechnology Investment Forum (BIF) the day after our event on 26 September 2013. This one day Investment forum will focus on new and early stage biomedical and med-tech companies from across the UK seeking seed stage to Series A funding. BIF provides an opportunity for companies to showcase their technology, objectives and financial requirements through a 15 minute presentation to a forum of VC and angel investors.
For more information on BIF 2013 please click here.
For delegates interested in both events and requiring accommodation for 25 September, One Nucleus has negotiated special rates with hotels in Cambridge and Whittlesford. Please contact aline@onenucleus.com for more details.